IPA — Immunoprecise Antibodies Share Price
0.000.00%
Last trade - 00:00- $20.59m
- $20.60m
- CA$24.52m
- 38
- 48
- 40
- 37
Growth & Value
| 12m Forecast Rolling | Industry | Market | |
|---|---|---|---|
| PE Ratio (f) | n/a | ||
| PEG Ratio (f) | n/a | ||
| EPS Growth (f) | n/a | ||
| Dividend Yield (f) | n/a | ||
| Valuation (ttm) | Industry | Market | |
|---|---|---|---|
| Price to Book Value | 1.14 | ||
| Price to Tang. Book | 1.77 | ||
| Price to Free Cashflow | n/a | ||
| Price to Sales | 1.19 | ||
| EV to EBITDA | n/a | ||
Shareholder Activity
| Type | Buy / Hold / Sell |
|---|---|
| Institutions | |
| Directors | |
| Community |
Guru Screens
Quality
| Name | Industry | Market | |
|---|---|---|---|
| Return on Capital | -138.43% | ||
| Return on Equity | -123.08% | ||
| Operating Margin | -211.13% | ||
Financial Summary
| Year End 30th Apr | Unit | 2020 | 2021 | 2022 | 2023 | 2024 | 2025E | 2026E | CAGR / Avg |
|---|---|---|---|---|---|---|---|---|---|
| Total Revenue | CA$m | 14.06 | 17.91 | 19.36 | 20.66 | 24.52 | 25.41 | 29 | 17.54% |
| Operating Profit | m | ||||||||
| Net Profit | m | ||||||||
| EPS Reported | |||||||||
| Diluted Normalised EPS | |||||||||
| EPS Growth | % | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
| PE Ratio | x | ||||||||
| PEG | |||||||||
| Profitability | |||||||||
| Operating Margin | % | ||||||||
| ROA | % | ||||||||
| ROCE | % | ||||||||
| ROE | % | ||||||||
| Cashflow | |||||||||
| Op. Cashflow ps | |||||||||
| Capex ps | |||||||||
| Free Cashflow ps | |||||||||
| Dividends | |||||||||
| Dividend ps | |||||||||
| Dividend Growth | % | ||||||||
| Dividend Yield | % | ||||||||
| Dividend Cover | x | ||||||||
| Balance Sheet | |||||||||
| Cash etc | m | ||||||||
| Working Capital | m | ||||||||
| NFA | m | ||||||||
| Net Debt | m | ||||||||
| Book Value | m | ||||||||
| Diluted Weighted Average Shares | m | ||||||||
| Book Value ps | |||||||||
Other Ratios
| Leverage (ttm) | Total | - Intang | + Pension |
|---|---|---|---|
| Gross Gearing | |||
| Net Gearing | |||
| Cash / Assets |
| Liquidity (ttm) | |
|---|---|
| Curr. Ratio | |
| Quick Ratio | |
| Interest Cov. | |
| Efficiency (ttm) | |
|---|---|
| Asset Turnover | |
| Recs Turnover | |
| Stock Turnover | |
Recent History
| Latest interim period vs. prior period | Industry | Market | |
|---|---|---|---|
| Sales Growth | |||
| EPS Growth | |||
| 3yr Compound Annual Growth Rate | Industry | Market | |
|---|---|---|---|
| Sales CAGR | |||
| EPS CAGR | |||
| DPS CAGR | |||
Profile Summary
ImmunoPrecise Antibodies Ltd. is a biotechnology company that leverages multi-omics modeling and complex artificial intelligence through a series of proprietary and patented technologies. The Company owns an integrated end-to-end suite of capabilities to support the development of therapeutic antibodies. It has several subsidiaries in North America and Europe including entities, such as Talem Therapeutics LLC, BioStrand BV, ImmunoPrecise Antibodies (Canada) Ltd. and ImmunoPrecise Antibodies (Europe) B.V. (collectively, the IPA Family). Its Contract Research Organizations (CRO) services include B cell Select; Phage Display; DeepDisplay; Abthena Bispecifics; LucinaTech Humanization; Affinity Maturation; Immunization, hybridoma, sequencing; rPEx protein manufacturing, and Cell line development. The Company utilizes custom antigen modeling, target analysis using Natural Language Processing and the HYFTTM analysis to lay the groundwork for the subsequent experimental phases.
Directors
- James Kuo NEC
- Jennifer Bath PRE
- Lisa Helbling CFO
- Ilse Roodink CSO
- Kari Graber VPR
- Stefan Lang OTH
- Paul Andreola IND
- Robert Burke IND
- Gregory Smith IND
- Last Annual
- April 30th, 2024
- Last Interim
- January 31st, 2025
- Incorporated
- September 2nd, 2016
- Public Since
- January 30th, 1987
- No. of Employees
- 102
- Sector
- Pharmaceuticals
- Industry
- Healthcare
- Exchange
- NASDAQ Capital Market
- Shares in Issue
- 45,765,118
- Address
- 3204-4464 Markham St., VICTORIA, V8Z 7X8
- Web
- https://www.ipatherapeutics.com/
- Phone
- +1 6048060626
- Auditors
- Grant Thornton LLP
Upcoming Events for IPA
Q1 2026 Immunoprecise Antibodies Ltd Earnings Release
Similar to IPA
60 Degrees Pharmaceuticals
NASDAQ Capital Market
Agriforce Growing Systems
NASDAQ Capital Market
Akari Therapeutics
NASDAQ Capital Market
Akebia Therapeutics
NASDAQ Capital Market
ASP Isotopes
NASDAQ Capital Market
FAQ
What is the Immunoprecise Antibodies share price?
As of Today at 21:15 UTC, shares in Immunoprecise Antibodies are trading at $0.45. This share price information is delayed by 15 minutes.
How has the Immunoprecise Antibodies share price performed this year?
Shares in Immunoprecise Antibodies last closed at $0.45 and the price had moved by -62.31% over the past 365 days. In terms of relative price strength the Immunoprecise Antibodies share price has underperformed the S&P500 Index by -65.21% over the past year.
What are the analyst and broker recommendations for Immunoprecise Antibodies?
The overall consensus recommendation for Immunoprecise Antibodies is Buy. You can view the full broker recommendation list by unlocking its StockReport.
Find out moreWhat is the Immunoprecise Antibodies dividend yield?
Immunoprecise Antibodies does not currently pay a dividend.
Does Immunoprecise Antibodies pay a dividend?
Immunoprecise Antibodies does not currently pay a dividend.
When does Immunoprecise Antibodies next pay dividends?
Immunoprecise Antibodies does not currently pay a dividend.
How do I buy Immunoprecise Antibodies shares?
To buy shares in Immunoprecise Antibodies you'll need a share-dealing account with an online or offline stock broker. Once you have opened your account and transferred funds into it, you'll be able to search and select shares to buy and sell. You can use Stockopedia’s share research software to help you find the the kinds of shares that suit your investment strategy and objectives.
What is the market cap of Immunoprecise Antibodies?
As of the previous close price of $0.45, shares in Immunoprecise Antibodies had a market capitalisation of $20.59m.
Where are Immunoprecise Antibodies shares listed?
Here are the trading details for Immunoprecise Antibodies:
- Country of listing: United States
- Exchange: NAQ
- Ticker Symbol: IPA
What kind of share is Immunoprecise Antibodies?
Based on an overall assessment of its quality, value and momentum Immunoprecise Antibodies is currently classified as a Neutral. The classification is based on a composite score that examines a wide range of fundamental and technical measures. Stock are classified on the the following spectrum: Super Stocks, High Flyers, Contrarians, Turnarounds, Neutral, Value Traps, Momentum Traps, Falling Stars, and Sucker Stocks. For more information, learn about our StockRank Styles.
Is there a Immunoprecise Antibodies share price forecast for 2025?
The analyst consensus target price for shares in Immunoprecise Antibodies is $4.01. That is 790.24% above the last closing price of $0.45.
Analysts covering Immunoprecise Antibodies currently have a consensus Earnings Per Share (EPS) forecast of -CA$0.63 for the next financial year.
Find out moreWhat is the trend in the Immunoprecise Antibodies share price?
An important predictor of whether a stock price will go up is its track record of momentum. Price trends tend to persist, so it's worth looking at them when it comes to a share like Immunoprecise Antibodies. Over the past six months, its share price has underperformed the S&P500 Index by -30.06%.
As of the last closing price of $0.45, shares in Immunoprecise Antibodies were trading -17.48% below their 200 day moving average. You can read more about the power of momentum in assessing share price movements on Stockopedia.
What is the Immunoprecise Antibodies PE Ratio?
The Immunoprecise Antibodies PE ratio based on its reported earnings over the past 12 months is null. The shares last closed at $0.45.
The PE ratio (or price-to-earnings ratio) is the one of the most popular valuation measures used by stock market investors. It is calculated by dividing a company's price per share by its earnings per share.
The PE ratio can be seen as being expressed in years, in the sense that it shows the number of years of earnings which would be required to pay back the purchase price, ignoring inflation. So in general terms, the higher the PE, the more expensive the stock is.
Who are the key directors of Immunoprecise Antibodies?
Immunoprecise Antibodies' management team is headed by:
- James Kuo - NEC
- Jennifer Bath - PRE
- Lisa Helbling - CFO
- Ilse Roodink - CSO
- Kari Graber - VPR
- Stefan Lang - OTH
- Paul Andreola - IND
- Robert Burke - IND
- Gregory Smith - IND